June 20, 2022
News release
BioPorto Appoints World Leading Expert and Pioneer on the Clinical Utility of the NGAL Biomarker, Dr. Prasad Devarajan, MD FAAP FASN, as New Senior Medical Director
COPENHAGEN, DENMARK and BOSTON, MA, USA, June 20, 2022, (GLOBE NEWSWIRE) — BioPorto A/S (CPH:BIOPOR) (BioPorto) today announced the appointment of Dr. Prasad Devarajan, MD FAAP FASN, as Senior Medical Director effective July 1, 2022.
Dr. Devarajan is considered a world leading Pediatric Nephrologist and physician-scientist and a pioneer in understanding the relationship between Neutrophil gelatinase-associated lipocalin (NGAL) and Acute Kidney Injury (AKI). Dr. Devarajan is Professor of Pediatrics & Developmental Biology, Director of Nephrology and Hypertension, and CEO of the Dialysis Unit at Cincinnati Children’s Hospital Medical Center (Ohio, USA). He is the author of much of the most frequently cited peer-reviewed literature on the topics of kidney disease, nephrology, and renal disease. Dr. Devarajan will share his time between his directorships at Cincinnati Children’s and his executive role at BioPorto.
“I am extremely excited and proud to have a world-renowned nephrologist and NGAL expert join BioPorto as Senior Medical Director,” said Tony Pare, BioPorto’s Chief Executive Officer. “Dr. Devarajan’s unparalleled reputation, knowledge, and expertise will be a tremendous gain for BioPorto as we expand the global market’s understanding of the benefits of The…
